HF
INDP icon

HRT Financial’s Indaptus Therapeutics INDP Stock Holding History

HRT Financial’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13
Closed -$21K – 1383
2019
Q3 		$21K Buy
+13
New +$38.7K ﹤0.01% 1337

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

HRT Financial's INDP Position: Q4 2019 in Review

HRT Financial sold out of Indaptus Therapeutics (INDP) in Q4 2019, closing a stake of 13 shares — an estimated $21K sold.

HRT Financial first reported a position in INDP in Q3 2019 and held it in 1 quarter. The position peaked at $21K in Q3 2019. 25 funds tracked by Wall St. Rank hold INDP as of Q4 2019.

  • HRT Financial reported no remaining Indaptus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • HRT Financial sold 13 Indaptus Therapeutics shares in Q4 2019, an estimated $21K.
  • HRT Financial first reported a position in Indaptus Therapeutics in Q3 2019 and held it in 1 quarter.
  • HRT Financial's Indaptus Therapeutics position peaked at $21K in Q3 2019.
  • 25 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2019.

Based on HRT Financial's 13F filing for Q4 2019, filed 14 Feb 2020.